RecruitingPhase 3NCT07209761
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
Studying Primary pulmonary tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Principal Investigator
- Simbarashe G Takuva, MD, MSc.Study Sponsor
- Intervention
- BPaQM(drug)
- Enrollment
- 532 target
- Eligibility
- 14 years · All sexes
- Timeline
- 2025 – 2028
Study locations (30)
- Capital Medical University - Beijing Chest Hospital, Beijing, Beijing Municipality, China
- The Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China
- Wuhan Institute of Tuberculosis Control (Wuhan Pulmonary Hospital), Wuhan, Hubei, China
- The Second Hospital of Nanjing, Nanjing, Jiangsu, China
- Shanghai Pulmonary Hospital - Pneumology, Shanghai, Shanghai Municipality, China
- Public Health Clinical Center of Chengdu, Chengdu, Sichuan, China
- National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia
- Japan Anti-Tuberculosis Association Fukujuji Hospital, Kiyose, Tokyo, Japan
- IMSP Institutul de Ftiziopneumologie Chiril Draganiuc - Phthisiopneumology, Chisinau, Chisinau City, Moldova
- Socios en Salud Sucursal Peru, La Molina, Lima region, Peru
- Centro de Investigación del Hospital de Emergencias de Villa el Salvador, Villa El Salvador, Lima region, Peru
- Hospital Sergio E. Bernales, Lima, Peru
- Silang Specialist Medical Center, Silang, Cavite, Philippines
- Jose B. Lingad Memorial Regional Hospital, San Fernando City, Central Luzon (Region III), Philippines
- Tropical Disease Foundation, Makati City, National Capital Region, Philippines
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07209761 on ClinicalTrials.govOther trials for Primary pulmonary tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07484490Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in TuberculosisRiphah International University
- RECRUITINGPHASE2NCT07170800A Phase 2b Clinical Study of JDB0131 Benzenesulfonate TabletsWestVac Biopharma Co., Ltd.
- RECRUITINGPHASE2NCT06192160Trial of Novel Regimens for the Treatment of Pulmonary TuberculosisNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGPHASE2NCT06748937A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With EthionamideTASK Applied Science
- ACTIVE NOT RECRUITINGNANCT07186478I-FALMIN Albumin Supplement for Patients With Pulmonary TuberculosisHasanuddin University
- ACTIVE NOT RECRUITINGPHASE3NCT06649721Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese CohortHuashan Hospital
- RECRUITINGPHASE4NCT06476210The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)Beijing Chest Hospital
- RECRUITINGPHASE2NCT06114628Platform Assessing Regimens and Durations In a Global Multisite Consortium for TBUniversity College, London